Apimeds Pharmaceuticals US (APUS) Accounts Payables (2023 - 2025)

Apimeds Pharmaceuticals US's Accounts Payables history runs 3 years deep, the most recent figure standing at $567633.0 for Q3 2025.

• Quarterly Accounts Payables changed N/A year-over-year to $567633.0 in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $567633.0 (changed N/A YoY) and the FY2024 annual result came in at $591191.0, up 985.99% from the prior year.
• Accounts Payables was $567633.0 for Q3 2025 at Apimeds Pharmaceuticals US, up from $119138.0 in the prior quarter.
• Across five years, Accounts Payables topped out at $935203.0 in Q1 2025 and bottomed at $54438.0 in Q4 2023.
• A 3-year average of $453520.6 and a median of $567633.0 in 2025 frame the typical range for Accounts Payables.
• Peak annual rise in Accounts Payables reached 985.99% in 2024, while the deepest fall reached 985.99% in 2024.
• Apimeds Pharmaceuticals US's Accounts Payables stood at $54438.0 in 2023, then surged by 985.99% to $591191.0 in 2024, then declined by 3.98% to $567633.0 in 2025.
• Business Quant data shows APUS's Accounts Payables at $567633.0 in Q3 2025, $119138.0 in Q2 2025, and $935203.0 in Q1 2025.